The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
Young professional boards, usually consisting of members ages 21 to 40, vary in size and responsibilities, but the groups are seen as a way to engage millennials.
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
One can argue that 200 years is the blink of an eye in the transcript of history. It’s remarkable to observe the progress that has transpired in Indiana since statehood was achieved in 1816.
It was the year of the improbable, especially in politics—starting with the resignation of Lt. Gov. Sue Ellspermann and ending with the election of Mike Pence as vice president. Then there was Carrier’s flip-flip, Eli Lilly’s changing of the guard, ITT Educational Services’ collapse—and much, much more.
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
Jim Schellinger, the incoming secretary of commerce, previously was president of the Indiana Economic Development Corp., a role that included frequent travel to communities across the state. In his new post, he'll be courting companies across the globe.
Eric Holcomb was a struggling Republican Senate candidate a year ago, a virtual unknown in Indiana despite more than a decade at the top levels of the Republican state politics. On Monday, he became Indiana’s chief executive.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
An iconic architectural landmark that would create a gateway to downtown is one of several features city officials want as part of a redevelopment of the former General Motors stamping plant site.
